Jan 30, 2024 / 12:00AM GMT
John Kelly - Atomo Diagnostics Ltd - Chief Executive Officer, Founder, Managing Director, Director
Hello, everyone, and welcome to the quarter 2 report from Atomo's FY '24 period. I'm John Kelly, the Managing Director of Atomo, and welcome this morning.
Before I jump into the quarterly, I just wanted to, I think, step back 12 months to the Q2 period for FY '23. At that stage, we had just come out of the COVID pandemic and Atomo, like a number of -- or most diagnostics companies, had seen a fairly abrupt end to COVID revenues. And there was a lot of uncertainty in the market around the future growth opportunities for diagnostics companies more broadly. And I think that uncertainty was reflected as well as the loss of COVID revenue was reflected in a lot of pressure on diagnostic companies share prices.
Atomo at that time said to shareholders that we were looking to refocus on our core business, which was essentially blood-based testing and that we knew 2 things. One, that our blood tests were best-in-class, and there would be a return to demand for them as our existing customers and
Q2 2024 Atomo Diagnostics Ltd Activities Report Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot